Loading…
Inflammatory Bowel Disease (IBD) has been closely linked to alterations in the gut microbiota, particularly an increase in the Proteobacteria phylum. This connection is highlighted in several studies, which have consistently observed elevated levels of Proteobacteria in individuals suffering from Inflammatory Bowel Disease (IBD). Notable research by Franzosa et al. in 2019 confirms this finding, emphasizing the prevalence of Proteobacteria in Inflammatory Bowel Disease (IBD) patients.
Further exploration into the microbial composition of Inflammatory Bowel Disease (IBD) patients reveals that specific bacteria within the Proteobacteria phylum, such as Escherichia coli, Campylobacter concisus, and enterohepatic Helicobacter, are frequently associated with the disease. Mukhopadhya et al. in their 2012 review in Nature Reviews Gastroenterology & Hepatology, discuss these associations in depth. They examine how genetic polymorphisms in innate immunity, alongside these microbial patterns, contribute to the pathogenesis of IBD. The review also underscores the importance of pattern recognition in the immune response, suggesting that disruptions in microbial balance, or dysbiosis, could lead to the development of IBD.
Additionally, the impact of fecal microbiota transplantation (FMT) on Inflammatory Bowel Disease (IBD) has been studied, with findings reported by Seekatz et al. in 2014. Their research indicates that after Fecal Microbiota Transplantation (FMT), there is a notable increase in the diversity of the recipient's microbiota and a corresponding decrease in the abundance of Proteobacteria. This suggests that FMT could potentially restore a healthier microbial balance in Inflammatory Bowel Disease (IBD) patients, offering a promising avenue for treatment.
. doi:10.1128/mBio.00893-14.
Overall, the evidence points to a significant role of Proteobacteria in the onset and progression of Inflammatory Bowel Disease, with implications for innovative treatments that target microbial imbalances.